A Phase II Study of EBV-Specific Cytotoxic T cells to Treat EBV Lymphomas or Other EBV-Related Cancers

Share
Print

Full Title

A Phase II Trial of EBV-specific cytotoxic T cells the treatment of EBV lymphomas or other EBV-associated malignancies

Purpose

The Epstein-Barr virus (EBV) is a common virus and is usually harmless. Once someone is infected, the virus remains dormant in the body for the rest of their lives. However, in some people, it can trigger tumors such as lymphomas. In people who do not have strong immune systems, such as those who have recently had a blood stem cell or organ transplant, the virus is especially likely to trigger tumor growth. The standard treatments for EBV-associated cancers include reduction of immunosuppressive drugs and treatment with chemotherapy and/or rituximab.

In this study, researchers are evaluating a treatment called EBV-specific cytotoxic T cells (EBV-CTLs) to treat patients with EBV-related lymphomas and other cancers. EBV-CTLs are made by taking immune cells from a specifically selected healthy donor and growing them in a laboratory for several weeks to educate them to recognize and destroy EBV-infected cells. These donor EBV-specific T cells are then frozen for future use. The donor’s EBV-CTLs are given intravenously (by vein).

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have EBV-related lymphoma or another EBV-related cancer due to an underlying immune deficiency.
  • In addition to patients with good physical function, this study is also open to those who are capable of only limited self-care and are confined to bed or chair for more than half of their normal waking hours.
  • This study is for patients of all ages.

For more information about this study and to inquire about eligibility, please contact Dr. Susan Prockop at 212-639-6715.

Protocol

18-315

Phase

II

Disease Status

Newly Diagnosed & Relapsed/Refractory

Investigator

Co-Investigators